Taiwan-based ICP DAS-BMP is set to present its cutting-edge medical-grade TPU portfolio and contract manufacturing services at Medical Manufacturing Asia 2026 in Singapore. The company will highlight innovations in low-migration and low-friction materials to enhance medical device safety and performance.
- ICP DAS-BMP will exhibit at Medical Manufacturing Asia 2026 at Marina Bay Sands, Singapore.
- Focus on Low-Migration and Low-Friction TPU series for enhanced patient safety.
- Offerings include ISO 13485 certified OEM/ODM and medical tubing extrusion services.
ICP DAS-BMP (Biomedical Polymers), a premier Taiwan-based manufacturer of medical-grade thermoplastic polyurethane (TPU), has announced its participation in Medical Manufacturing Asia 2026. The event will take place from September 9–11 at the Marina Bay Sands Expo & Convention Centre in Singapore (Booth 2U20). In collaboration with its manufacturing partner, Towards Buddha Co., Ltd., the company aims to showcase a comprehensive suite of TPU solutions and integrated contract manufacturing (OEM/ODM) services.
The centerpiece of the exhibit will be two groundbreaking TPU innovations designed to solve critical challenges in the medical device industry. The Low-Migration Series, specifically the Arothane™ ARP-B20 TPU, is engineered to comply with ISO 10993 standards and is suitable for implantation for up to 90 days. Its advanced formulation significantly reduces the migration of additives to the device surface, ensuring long-term chemical stability and biocompatibility.
Simultaneously, the Low-Friction Series is set to redefine invasive procedure comfort. By providing an inherently smooth surface, this TPU eliminates the need for secondary coatings or post-processing. Being PFAS-free and plasticizer-free, it allows medical professionals to handle invasive catheters, such as nasogastric tubes and central venous catheters, with superior control and reduced patient trauma.
Why This Matters
BozokMedia analysis shows that the shift toward specialized medical polymers is a response to the tightening global regulatory environment regarding PFAS and additive leaching. By integrating smart factory practices inherited from its parent company, ICP DAS, the firm is not just selling materials but optimizing the entire supply chain—from material selection to extrusion. This vertical integration is crucial for medical device OEMs looking to reduce time-to-market without compromising on ISO safety standards.
"The transition toward PFAS-free, low-friction medical polymers is no longer optional; it is a regulatory and ethical imperative for the next generation of implantable devices."
Beyond these highlights, ICP DAS-BMP will present its wider portfolio, including the ARP, ALP, and ALC series, which cater to limited, prolonged, and long-term contact durations. For applications requiring X-ray visibility, the company offers the ARP/ALP/ALC-B20/B40 series (containing 20–40% barium sulfate) and the ARP-W/WG series (containing 40–60% tungsten). Additionally, the Engineering Arothane™ EARP series will be showcased for high-precision components like Luer-Lock connectors and orthodontic parts.
| Series/Product | Key Feature | Primary Application |
|---|---|---|
| Low-Migration (ARP-B20) | Minimized additive leaching | Short-term implants (up to 90 days) |
| Low-Friction Series | PFAS-free, inherent smoothness | Invasive catheters & NG tubes |
| Radiopaque Series | Barium/Tungsten infused | X-ray visible medical devices |
| EARP Series | High clarity & mechanical strength | Orthodontic & precision connectors |
Frequently Asked Questions
1. What is the primary advantage of Low-Friction TPU?
It provides a naturally smooth surface without needing chemical coatings, reducing friction during catheter insertion and improving patient comfort.
2. Does ICP DAS-BMP support small-batch orders?
Yes, the company emphasizes flexible solutions and responsive support, catering to both large-scale production and smaller, specialized order quantities.
